5 EASY FACTS ABOUT IS ABBV-744 EFFECTIVE FOR HEMATOLOGIC CANCERS? DESCRIBED

In Phase C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment until disorder progression or even the members are unable to tolerate the study drugs.88 These preclinical studies give paradigms for future clinical trials in AML, and the use of novel comb